Groundbreaking Advancement in Fetal Monitoring Technology
Huntleigh Healthcare is thrilled to announce that their innovative Dawes-Redman CTG Analysis™ has gained approval for use in the U.S. by the Food and Drug Administration (FDA). This major milestone is set to assist healthcare providers in enhancing the interpretation of fetal heart monitoring traces, ultimately leading to improved outcomes for families and their newborns.
Understanding the Dawes-Redman CTG Analysis™
The Dawes-Redman analysis focuses on evaluating non-stress test (NST) traces to determine if they meet established criteria for normality. This analysis has been developed from an extensive database comprising over 100,000 NST traces and their respective outcomes. Key factors assessed by the analysis include basal heart rate, sinusoidal patterns, and the short-term variation (STV) of the fetal heart rate, which are challenging to calculate without advanced technology.
A Significant Step Forward
Gang Zhang, Managing Director of Huntleigh Healthcare, expressed excitement about this development, stating, "Introducing the Dawes Redman analysis to the U.S. signifies a major advancement towards a modernized approach to maternity care. This objective evaluation empowers clinicians with deeper insights, thus ensuring clarity and reassurance during crucial moments in fetal monitoring."
Long-Term Research and Development
The Dawes Redman algorithm has been meticulously refined over the course of four decades, supported by over 125 peer-reviewed academic articles published worldwide. This background underlines its effectiveness in identifying fetal wellbeing through rigorous evaluation metrics.
Accelerated Analysis for Better Care
Thanks to collaborative efforts from a team at the University of Oxford, the analysis can now process healthy NST traces in as little as 10 minutes—significantly quicker than the typical 30 minutes a healthcare provider may require.
Exclusive Availability of the Technology
The Dawes-Redman CTG Analysis is integrated into Huntleigh's Sonicaid™ TEAM3 series of fetal monitors, alongside the OBIX BeCA fetal monitor distributed in the U.S. by Clinical Computer Systems Incorporated. The exclusive provision of this unparalleled technology highlights Huntleigh's commitment to advancing fetal monitoring standards.
A Legacy of Innovation
The Dawes-Redman algorithm traces its roots back to the pioneering work of Professors Geoffrey Dawes and Chris Redman at Oxford University. Huntleigh has held exclusive distribution rights for this analysis since it first became commercially available, and continues to drive innovation in the field.
Global Implementation and Recognition
This advanced analysis has gained international recognition, as it has been employed worldwide to enhance NST interpretation, thereby aiding clinicians in making critical, life-saving decisions for mothers and their infants. It has been specifically mentioned in NHS England's 'Saving Babies Lives' care bundle, signifying the importance of computerized CTG analysis in future healthcare strategies.
Positive Reactions from Leadership
Todd Blockinger, Business Unit Director for Huntleigh in the U.S., shared his enthusiasm: "We are incredibly excited to introduce Dawes Redman to the U.S. Our colleagues internationally have benefited from this life-saving technology, and we can’t wait to share its advantages with American maternal care professionals. The dedication to improving the healthcare landscape for mothers and babies is central to our mission."
About Huntleigh Healthcare
As part of the Arjo family, Huntleigh Healthcare is a UK-based manufacturer and a leading provider of innovative medical equipment tailored for healthcare professionals. With renowned brands like Sonicaid™, Dopplex®, Hydroven®, and Smartsigns®, Huntleigh fulfills a diverse range of healthcare needs across obstetrics, vascular assessment and treatment, and patient monitoring.
Continuing Commitment to Maternity Innovation
Boasting over 40 years of experience, Huntleigh alongside the Sonicaid brand has been committed to maternity product innovation, continually developing a leading array of fetal Dopplers and Monitors. Their product lineup is complemented by extensive software systems designed for every type of maternity environment, from single-user setups to fully integrated installations.
Frequently Asked Questions
What is the significance of the FDA approval for Dawes-Redman CTG Analysis?
The FDA approval enables Huntleigh Healthcare to offer a proven tool that enhances the accuracy of fetal heart monitoring, improving outcomes for mothers and newborns.
How does the Dawes-Redman Analysis work?
The analysis assesses NST traces by evaluating critical factors like heart rate and rhythms using a database of over 100,000 cases, ensuring precise care based on the latest data.
Why is the analysis essential for clinicians?
This analysis provides healthcare professionals with objective insights, enabling them to make informed decisions during pregnancy, leading to better care.
Is this technology available in other regions?
The Dawes-Redman CTG Analysis has been utilized worldwide, enhancing fetal monitoring practices globally, with a focus on reducing maternal and neonatal risks.
What future developments can we expect from Huntleigh Healthcare?
Huntleigh remains focused on advancing healthcare technology, with ongoing research and product development to support clinicians and enhance patient care experiences.
